Travere Q2 FILSPARI sales $27.1M, up 37% Q/Q; 521 new patient start forms

Travere Therapeutics, Inc.

2024-Q2 EPS reported -$2.67 revenue$95,490,000

Net product sales $52.2M (incl. $27.1M FILSPARI); total revenue $54.1M.
Net loss $70.4M ($0.91/share); adjusted net loss $50.1M ($0.65/share).
Cash & equivalents $325.4M at June 30, 2024.
PDUFA target date Sept 5, 2024 for FILSPARI full approval in IgAN.
Received 521 PSFs in Q2; 2,484 total since launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.